Improving CAR T cell therapy to reduce harmful side effects
Ameliorating off-target toxicities of CAR T cells by engineering NOT gates
['FUNDING_R01'] · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · NIH-10892156
This study is looking at ways to make CAR T cell therapy safer and more effective for people with solid tumors by creating special T cells that can tell the difference between cancer cells and healthy tissue, helping to reduce side effects.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO (nih funded) |
| Locations | 1 site (SAN FRANCISCO, UNITED STATES) |
| Trial ID | NIH-10892156 on ClinicalTrials.gov |
What this research studies
This research focuses on enhancing CAR T cell therapy, which has been effective for treating B cell cancers, by developing new methods to prevent harmful side effects when targeting solid tumors. The approach involves engineering T cells with multi-receptor circuits that can distinguish between cancerous and normal tissues, thereby reducing the risk of off-target toxicity. By using bioinformatics to identify specific antigens that are unique to healthy tissues, the researchers aim to create circuits that deactivate CAR T cells when they encounter these antigens. This innovative strategy could lead to safer and more effective treatments for patients with solid tumors.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with solid tumors who may benefit from CAR T cell therapy but are at risk of off-target effects.
Not a fit: Patients with B cell cancers who are already effectively treated with existing CAR T cell therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to safer CAR T cell therapies that minimize harmful side effects for patients with solid tumors.
How similar studies have performed: While CAR T cell therapies have shown success in treating B cell cancers, the approach of using NOT gate circuits for solid tumors is novel and has not been widely tested.
Where this research is happening
SAN FRANCISCO, UNITED STATES
- UNIVERSITY OF CALIFORNIA, SAN FRANCISCO — SAN FRANCISCO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: LIM, WENDELL A — UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
- Study coordinator: LIM, WENDELL A
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.